R&D | March 19, 2026
IIT Roorkee unveils cutting-edge molecular medicine facility
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Subscribe To Our Newsletter & Stay Updated
